Effect of combined pioglitazoneexenatide therapy on plasma adiponectinlipid metabolism in type 2diabetes

Jogi, Medhavi; Sathyanarayana, Sheela

doi:10.1016/s1499-2671(09)33269-4

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After 3.5 years of exenatide twice-daily treatment in an open-label study, the quarter of patients who experienced the largest mean weight loss (12.8 kg) also had the greatest mean changes in SBP (−8.1 mmHg), high-density lipoprotein cholesterol (HDL-C) (+10.6 mg/dl) and triglycerides (−104.2 mg/dl) [71], despite a minimal correlation in the overall results between weight loss and lipid changes [71]. Further research is necessary to determine the actual mechanism for the improvements in blood pressure and the modest but significant reductions in triglycerides, free fatty acids and low-density lipoprotein cholesterol (LDL-C) levels that result with GLP-1 RA treatments [54,72]. Furthermore, a significant increase in HDL-C has also been observed in some studies [71,73].…”

Section: Blood Pressure Lipids and Other Cardiovascular Risk Factorsmentioning

confidence: 99%

Comparison of liraglutide versus other incretin‐related anti‐hyperglycaemic agents

Blonde

Montanya

2012

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

The two classes of incretin-related therapies, dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), have become important treatment options for patients with type 2 diabetes. Sitagliptin, saxagliptin, vildagliptin and linagliptin, the available DPP-4 inhibitors, are oral medications, whereas the GLP-1 RAs-twice-daily exenatide, once-weekly exenatide and once-daily liraglutide-are administered subcutaneously. By influencing levels of GLP-1 receptor stimulation, these medications lower plasma glucose levels in a glucose-dependent manner with low risk of hypoglycaemia, affecting postprandial plasma glucose more than most other antihyperglycaemic medications. Use of GLP-1 RAs has been shown to result in greater glycaemic improvements than DPP-4 inhibitors, probably because of higher levels of GLP-1 receptor activation. GLP-1 RAs can also produce significant weight loss and may reduce blood pressure and have beneficial effects on other cardiovascular risk factors. Although both classes are well tolerated, DPP-4 inhibitors may be associated with infections and headaches, whereas GLP-1 RAs are often associated with gastrointestinal disorders, primarily nausea. Pancreatitis has been reported with both DPP-4 inhibitors and GLP-1 RAs, but a causal relationship between use of incretin-based therapies and pancreatitis has not been established. In clinical trials, liraglutide has shown efficacy and tolerability and resulted in certain significant benefits when compared with exenatide and sitagliptin.

show abstract

Section: Blood Pressure Lipids and Other Cardiovascular Risk Factorsmentioning

confidence: 99%

Comparison of liraglutide versus other incretin‐related anti‐hyperglycaemic agents

Blonde

Montanya

2012

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

Effect of combined pioglitazoneexenatide therapy on plasma adiponectinlipid metabolism in type 2diabetes

Cited by 1 publication

References 0 publications

Comparison of liraglutide versus other incretin‐related anti‐hyperglycaemic agents

Comparison of liraglutide versus other incretin‐related anti‐hyperglycaemic agents

Contact Info

Product

Resources

About